FDA — authorised 12 May 1998
- Application: BLA103764
- Marketing authorisation holder: NOVARTIS
- Status: supplemented
FDA authorised Simulect on 12 May 1998
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA authorised it on 12 May 1998; FDA has authorised it.
NOVARTIS holds the US marketing authorisation.